TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GRI Bio ( (GRI) ) just unveiled an announcement.
GRI Bio‘s recent corporate presentation highlights the advancement of its pipeline, particularly the development of NKT cell modulators for treating inflammatory diseases. The company has reported positive interim data for its GRI-0621 program, with expectations for further data in Q3 2025, positioning itself as a potential competitor to leading treatments like OFEV®.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio operates in the biotechnology industry, focusing on developing innovative treatments for inflammatory, fibrotic, and autoimmune diseases. The company leverages Natural Killer T (NKT) cell modulation to target diseases earlier in the inflammatory cascade, offering potential competitive advantages in the market.
Average Trading Volume: 239,002
Technical Sentiment Signal: Sell
Current Market Cap: $3.7M
Learn more about GRI stock on TipRanks’ Stock Analysis page.